| Kidney Carcinoma studied in …STUDIED_INderived200 of 1,681show all (up to 200) |
|---|
| → studied in | NCT04071223Phase 2 · active not recruiting Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07594106Phase 1/Phase 2 · recruiting REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03741426Phase 2 · recruiting WIRE - Novel Treatments in Renal Cell Cancer · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04626479Phase 1/Phase 2 · completed Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) · condition mapped ALIAS · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04626518Phase 1/Phase 2 · completed Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) · condition mapped ALIAS · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04981119recruiting Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07024680completed Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Papillary Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07124000recruiting DESTINY-PANTUMOUR04 · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07489495Phase 3 · recruiting A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) · condition mapped ALIAS · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07704970NA · recruiting QLESP Block for Pain Control in Robotic Partial Nephrectomy · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07748988Phase 1 · recruiting Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Chromophobe Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04489771Phase 2 · completed A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) · condition mapped ALIAS · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05188118early Phase 1 · completed Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06047379Phase 1/Phase 2 · recruiting Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07438626Phase 2 · recruiting Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma · condition mapped ALIAS · 1,681 trials mapped (472 active) | — | — | SMARCB1-Deficient Kidney Medullary Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07840001Phase 2 · not yet recruiting Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03981497recruiting Microwave Ablation for Treatment of Small Renal Tumors and Primary and Secondary Liver Neoplasms · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05987241Phase 2/Phase 3 · recruiting Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Muscle Invasive Renal Pelvis Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07293351Phase 1/Phase 2 · recruiting A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04810078Phase 3 · active not recruiting A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04963153Phase 1 · active not recruiting Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Pelvis Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06863311Phase 2 · recruiting Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07833085NA · not yet recruiting CAIX-targeted PET/CT in Solid Tumors · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03635892Phase 2 · active not recruiting A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma · condition mapped PROBABILISTIC · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05048212Phase 2 · recruiting A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05327686Phase 2 · recruiting Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05863052active not recruiting Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07688187Phase 1 · recruiting A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07827482completed Pretreatment 18F-FDG PET/CT Radiomics for Predicting Response to First-Line Targeted Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07828249Phase 1 · not yet recruiting Phase I Study Evaluating 161Tb-PSMA Therapy in Adult Patients With Metastatic Clear Cell Renal Cell Carcinoma · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04544748Phase 1 · completed A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies · condition mapped ALIAS · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05252585Phase 4 · active not recruiting A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) · condition mapped ALIAS · 1,681 trials mapped (472 active) | — | — | Kidney Angiomyolipoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06916624recruiting Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07049926Phase 1/Phase 2 · recruiting Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07172802Phase 1/Phase 2 · recruiting A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07227415Phase 1/Phase 2 · recruiting Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer · condition mapped ALIAS · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07297667Phase 1 · recruiting GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07576725Phase 2 · not yet recruiting Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07667335Phase 1/Phase 2 · recruiting Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Pelvis Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02974738Phase 1 · active not recruiting A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) · condition mapped ALIAS · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04467021NA · active not recruiting Cancer and Blood Pressure Management, CARISMA Study · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04940299Phase 2 · active not recruiting Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Pelvis Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05155033Phase 2 · recruiting Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05319015Phase 2 · recruiting Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05831891Phase 2 · active not recruiting Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Non-Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04969315Phase 1/Phase 2 · recruiting TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05863351Phase 3 · active not recruiting Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02812420early Phase 1 · active not recruiting Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery · condition mapped ALIAS · 1,681 trials mapped (472 active) | — | — | Invasive Renal Pelvis Sarcomatoid Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04140526Phase 1/Phase 2 · active not recruiting Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04977453Phase 1/Phase 2 · recruiting GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors · condition mapped ALIAS · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05012371Phase 2 · active not recruiting Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05059444recruiting ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Renal Pelvis Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05858736Phase 1 · completed Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06500455Phase 3 · active not recruiting Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06722807NA · suspended ClAmpless, Sutureless PartIAl Nephrectomy for Renal Masses · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07516366Phase 2 · recruiting Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07816770Phase 2 · not yet recruiting MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary Carcinomas · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Non-Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06708949Phase 2 · active not recruiting A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07181720Phase 1 · suspended CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02496208Phase 1 · active not recruiting Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05877820Phase 2 · completed A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Fumarate Hydratase-Deficient Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06480565Phase 1/Phase 2 · active not recruiting A Phase 1/2 Trial of ADI-270 in ccRCC · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01480154Phase 1 · active not recruiting Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05287945Phase 1/Phase 2 · recruiting Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma · condition mapped ALIAS · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07256223Phase 2 · not yet recruiting A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread · condition mapped ALIAS · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04707248Phase 1 · active not recruiting A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06465069Phase 1 · recruiting A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors · condition mapped ALIAS · 1,681 trials mapped (472 active) | — | — | Renal Pelvis Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06794229Phase 2 · recruiting Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07188896Phase 2 · recruiting A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07805122NA · recruiting Intensified Monitoring of PhArmacology of Cabozantinib as a Tool for Toxicity Management in Patients With Renal Cell Carcinoma · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02978118active not recruiting Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers) · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05411081Phase 2 · active not recruiting Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Papillary Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04981509Phase 2 · recruiting Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Hereditary Leiomyomatosis and Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05334069recruiting Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Kidney Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05837767NA · recruiting A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06661720Phase 3 · recruiting Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06745609NA · active not recruiting Prehabilitation Prior to Surgery for Kidney Tumors · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07011719Phase 3 · recruiting Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03647878active not recruiting Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment. · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04106349active not recruiting Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC) · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07636148recruiting Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03793166Phase 3 · active not recruiting Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03948724NA · completed Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04006522Phase 2 · active not recruiting 89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05536141Phase 1 · recruiting A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05830058Phase 2 · recruiting Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05891171Phase 1 · active not recruiting Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07077161Phase 2 · recruiting Cabozantinib Dose Skipping as an Alternative to Dose Reductions · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Kidney Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02867592Phase 2 · active not recruiting Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03055013Phase 3 · active not recruiting Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03595124Phase 2 · active not recruiting A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04090710Phase 2 · completed SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04669860suspended Evaluating the Bacterial and Fungal Microbiome in Patients With Calcium Oxalate Urolithiasis and Renal Cell Carcinoma · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06582017Phase 1 · recruiting Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01216371Phase 2 · terminated Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT) · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02568267Phase 2 · active not recruiting Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04670445NA · completed Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00001238recruiting Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00902590active not recruiting A Genotype-Phenotype Urothelial Cancer Registry · condition mapped ALIAS · 1,681 trials mapped (472 active) | — | — | Renal Pelvis Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03141177Phase 3 · completed A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04147494early Phase 1 · active not recruiting Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Kidney Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06432036Phase 1/Phase 2 · recruiting Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07623369Phase 1 · recruiting A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03274258Phase 2 · terminated Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Kidney Medullary Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04473781Phase 1 · terminated Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05269381Phase 1/Phase 2 · recruiting Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05468697Phase 1/Phase 2 · active not recruiting A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024) · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05899049Phase 3 · active not recruiting A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06940518Phase 2 · recruiting Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma · condition mapped PROBABILISTIC · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07123090Phase 2 · recruiting A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07187778Phase 2 · recruiting Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE) · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07714018NA · recruiting Comparing Two Weight Loss Programs for the Prevention of Kidney Cancer Progression Among Patients With Small Renal Masses on Active Surveillance · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07776483not yet recruiting Personalized ctDNA Monitoring for Predicting Immunotherapy Outcomes in Advanced Non-Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Non-Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07776717Phase 2 · not yet recruiting TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell Carcinoma · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04788095NA · active not recruiting App-Based Mindfulness Intervention for the Improvement of Quality of Life in Patients With Metastatic Renal Cell Cancer · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05361720Phase 2 · recruiting Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07115043Phase 1/Phase 2 · recruiting A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07636785Phase 1/Phase 2 · recruiting A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06966024Phase 1 · recruiting Study of DCC-2812 in Participants With Advanced Genitourinary Cancers · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07160335Phase 1 · active not recruiting A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07620574Phase 3 · enrolling by invitation Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07770802Phase 1 · not yet recruiting Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04895709Phase 1/Phase 2 · recruiting A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06792552Phase 1 · recruiting A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07768306Phase 1 · not yet recruiting Evaluation of Safety, Pharmacokinetics, Distribution，Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in Participants With IRM · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04736706Phase 3 · active not recruiting A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06284564Phase 2 · active not recruiting A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01038778Phase 1/Phase 2 · active not recruiting Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Kidney Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02830724Phase 1/Phase 2 · recruiting Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05733715early Phase 1 · recruiting Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06161532Phase 2 · recruiting Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C... · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Renal Medullary Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03587662Phase 2 · completed Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Kidney Medullary Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05706129Phase 1/Phase 2 · recruiting A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06242470Phase 1 · recruiting A Study of MGC026 in Participants With Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07187869Phase 1 · recruiting Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07195682Phase 1 · recruiting A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07239596Phase 1/Phase 2 · recruiting Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07615348Phase 2 · recruiting CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01575548Phase 3 · active not recruiting Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05805501Phase 2 · active not recruiting A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07753343recruiting Identification and Description of Patients With High-risk Non Metastatic RCC · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03991130Phase 2 · terminated High Dose IL-2 in Combination With Anti-PD-1 · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05581004Phase 1 · active not recruiting A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05725421NA · not yet recruiting Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06444880Phase 2 · active not recruiting Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Renal Medullary Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07716735Phase 1 · not yet recruiting Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Kidney Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04919122active not recruiting Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05176483Phase 1 · recruiting Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06910657Phase 1 · recruiting IDOV-Immune for Advanced Solid Tumors · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07226544Phase 2 · recruiting Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06076538recruiting PET/MR for Characterization of Renal Masses (RMs) · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07689812NA · not yet recruiting A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05433142Phase 1 · recruiting Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07000149Phase 1 · active not recruiting A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07227402Phase 3 · recruiting A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07300241Phase 1 · recruiting Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07611825Phase 2 · recruiting Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell Carcinoma · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03237780Phase 2 · active not recruiting Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Pelvis Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03284385Phase 2 · active not recruiting Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03945773Phase 2 · completed Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05703854Phase 1/Phase 2 · suspended Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05759923Phase 1 · recruiting First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06866262Phase 1/Phase 2 · recruiting Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07419841Phase 1 · recruiting A Phase 1 Study of the Safety and Tolerability of CTX-10726 · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02718066Phase 1/Phase 2 · completed Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05663710Phase 1/Phase 2 · recruiting Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07179770Phase 1 · recruiting Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC) · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07285044Phase 2 · recruiting The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07634380Phase 1 · recruiting Sitagliptin With Pembro in RCC and Melanoma · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04113486recruiting Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04198766Phase 1/Phase 2 · recruiting Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05665361Phase 1/Phase 2 · recruiting Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) · condition mapped ALIAS · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05678673Phase 3 · active not recruiting Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Non-Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07564232Phase 1 · recruiting Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05263050Phase 2 · recruiting Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07043608Phase 2 · recruiting Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases · condition mapped ALIAS · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00102544NA · enrolling by invitation Use of Tracking Devices to Locate Abnormalities During Invasive Procedures · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02306954Phase 2 · active not recruiting Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04413123Phase 2 · active not recruiting Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Papillary Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05714553Phase 1/Phase 2 · terminated NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06586658early Phase 1 · suspended Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or Relapsed/Metastatic CD70+ Inoperable Renal Cells · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06942104Phase 1 · recruiting Imaging of Solid Tumors Using 18F-TRX · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02298959Phase 1 · active not recruiting Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06049576Phase 1 · active not recruiting Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07062549Phase 1 · recruiting Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07077083Phase 2 · not yet recruiting CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07715565Phase 2 · not yet recruiting Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02721732Phase 2 · active not recruiting Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Kidney Medullary Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05078047Phase 3 · active not recruiting Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03541902Phase 2 · active not recruiting Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05092373Phase 1 · recruiting Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05501054Phase 1/Phase 2 · active not recruiting Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07128680Phase 1 · recruiting Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07671417early Phase 1 · not yet recruiting Imaging Study in Metastatic Clear Cell RCC. · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04374877Phase 1 · completed Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03091192Phase 3 · active not recruiting Savolitinib vs. Sunitinib in MET-driven PRCC. · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03374267recruiting Registry Platform Urologic Cancer · condition mapped CURATED_BROADER · 1,681 trials mapped (472 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05286801Phase 1/Phase 2 · active not recruiting Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors · condition mapped ONTOLOGY_EXACT · 1,681 trials mapped (472 active) | — | — | Kidney Medullary Carcinoma | 1 | Observed | clinicaltrials | graph → |